Literature DB >> 9382060

Increased gastric and intestinal permeability in patients with Crohn's disease.

J Wyatt1, G Oberhuber, S Pongratz, A Püspök, G Moser, G Novacek, H Lochs, H Vogelsang.   

Abstract

OBJECTIVES: Patients with Crohn's disease exhibit marked changes in intestinal permeability that can be assessed by lactulose and mannitol. Sucrose is a novel marker for gastric permeability. We combined these three sugars to investigate whether patients with Crohn's disease demonstrate changes in gastric permeability and if so, whether these changes are matched with altered intestinal permeability.
METHODS: Fifty patients with Crohn's disease and 30 healthy subjects each drank a solution containing 20 g of sucrose, 10 g of lactulose, and 5 g of mannitol. Patients' and subjects' 5-h sugar urinary excretion levels were determined by high performance liquid chromatography and an enzymatic method (sucrose). Furthermore, patients with Crohn's disease underwent endoscopy of the upper GI tract and were grouped according to endoscopic and histological findings.
RESULTS: Patients with Crohn's disease showed higher gastric and intestinal permeability compared with healthy control subjects. Gastric permeability was correlated with intestinal permeability. Patients with granuloma had more pronounced changes in both gastric and intestinal permeability than patients with various endoscopic and histological lesions. Patients with normal mucosa had normal permeability.
CONCLUSIONS: Alterations in gastric mucosa caused by Crohn's disease are reflected by changes in gastric permeability and can be used to noninvasively screen for Crohn's disease involvement of the upper GI tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382060

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

1.  Non-invasive assessment of barrier integrity and function of the human gut.

Authors:  Joep Grootjans; Geertje Thuijls; Froukje Verdam; Joep Pm Derikx; Kaatje Lenaerts; Wim A Buurman
Journal:  World J Gastrointest Surg       Date:  2010-03-27

Review 2.  The measurement and clinical significance of intestinal permeability.

Authors:  Christopher W Teshima; Jon B Meddings
Journal:  Curr Gastroenterol Rep       Date:  2008-10

Review 3.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

4.  Effects of aspirin on gastroduodenal permeability in alcoholics and controls.

Authors:  Ashkan Farhadi; Ali Keshavarzian; Mary J Kwasny; Maliha Shaikh; Louis Fogg; Cynthia Lau; Jeremy Z Fields; Christopher B Forsyth
Journal:  Alcohol       Date:  2010-07-03       Impact factor: 2.405

Review 5.  Immunology of inflammatory bowel disease and molecular targets for biologics.

Authors:  Maneesh Dave; Konstantinos A Papadakis; William A Faubion
Journal:  Gastroenterol Clin North Am       Date:  2014-09       Impact factor: 3.806

6.  Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease.

Authors:  Garth R Swanson; Shahriar Sedghi; Ashkan Farhadi; Ali Keshavarzian
Journal:  Alcohol       Date:  2010-05       Impact factor: 2.405

Review 7.  Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance.

Authors:  Mohtashem Samsam; Raheleh Ahangari; Saleh A Naser
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 8.  Working out mechanisms of controlled/physiologic inflammation in the GI tract.

Authors:  Keren Rabinowitz; Lloyd Mayer
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

9.  Is moderate red wine consumption safe in inactive inflammatory bowel disease?

Authors:  Garth R Swanson; Vanessa Tieu; Maliha Shaikh; Chris Forsyth; Ali Keshavarzian
Journal:  Digestion       Date:  2011-08-26       Impact factor: 3.216

Review 10.  The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.

Authors:  Shahryar Khaleghi; Josephine M Ju; Abhinav Lamba; Joseph A Murray
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.